vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
FrontView REIT, Inc. is the larger business by last-quarter revenue ($16.5M vs $12.6M, roughly 1.3× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -24.9%, a 275.6% gap on every dollar of revenue.
FVR vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $12.6M |
| Net Profit | $-4.1M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -24.9% | 250.7% |
| Revenue YoY | — | 24080.8% |
| Net Profit YoY | — | 250.9% |
| EPS (diluted) | $-0.19 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $12.6M | ||
| Q3 25 | $16.8M | $0 | ||
| Q2 25 | $17.6M | $0 | ||
| Q1 25 | $16.2M | $12.0K | ||
| Q4 24 | — | $52.0K | ||
| Q3 24 | $14.5M | $65.0K | ||
| Q2 24 | — | $114.0K | ||
| Q1 24 | — | $140.0K |
| Q4 25 | $-4.1M | $31.5M | ||
| Q3 25 | $4.0M | $-7.4M | ||
| Q2 25 | $-2.9M | $-1.7M | ||
| Q1 25 | $-833.0K | $-13.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.4M | $-17.1M | ||
| Q2 24 | — | $-17.9M | ||
| Q1 24 | — | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | -24.9% | 250.7% | ||
| Q3 25 | 23.9% | — | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -5.1% | -115550.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -16.7% | -26380.0% | ||
| Q2 24 | — | -15668.4% | ||
| Q1 24 | — | -9049.3% |
| Q4 25 | $-0.19 | $0.56 | ||
| Q3 25 | $0.19 | $-0.13 | ||
| Q2 25 | $-0.16 | $-0.03 | ||
| Q1 25 | $-0.06 | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $40.3M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $59.0M |
| Total Assets | $854.4M | $68.9M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $40.3M | ||
| Q3 25 | $19.6M | $48.6M | ||
| Q2 25 | $8.4M | $31.2M | ||
| Q1 25 | $3.3M | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | — | $63.5M | ||
| Q1 24 | — | $82.3M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $391.2M | $59.0M | ||
| Q3 25 | $385.2M | $26.5M | ||
| Q2 25 | $369.9M | $32.8M | ||
| Q1 25 | $324.7M | $33.8M | ||
| Q4 24 | — | $46.1M | ||
| Q3 24 | $1.0K | $65.5M | ||
| Q2 24 | — | $80.5M | ||
| Q1 24 | — | $96.2M |
| Q4 25 | $854.4M | $68.9M | ||
| Q3 25 | $846.8M | $54.2M | ||
| Q2 25 | $856.5M | $62.1M | ||
| Q1 25 | $860.8M | $77.7M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | $1.0K | $135.2M | ||
| Q2 24 | — | $149.9M | ||
| Q1 24 | — | $167.7M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $-8.4M | ||
| Q3 25 | $8.3M | $17.4M | ||
| Q2 25 | $9.3M | $-17.7M | ||
| Q1 25 | $8.1M | $-4.0M | ||
| Q4 24 | — | $-23.4M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | — | $-18.7M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
